Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma

Urothelial carcinoma (UC) occupies a high incidence among all the genitourinary malignancies. Immune checkpoint inhibitors (ICIs), as alternative treatments of metastatic urothelial carcinoma (mUC), have been applied in the treatment of mUC after chemotherapy failure, with comparable efficacy and sa...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Di Wang, Kai Sun, Tianqi Wang, Dongxu Zhang, Fengze Sun, Yuanshan Cui, Hongwei Zhao, Jitao Wu
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2021-11-01
Saila:	Frontiers in Pharmacology
Gaiak:	urothelial carcinoma (UC) immune checkpoint inhibitor (ICI) immune-related adverse events (irAEs) programmed cell death protein 1 (PD1) programmed cell death ligand protein 1 (PD-L1)
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fphar.2021.710943/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!